Severe Pegaspargase Hypersensitivity Reaction Rates (grade ≥3) with Intravenous Infusion vs. Intramuscular Injection: Analysis of 54,280 Doses Administered to 16,534 Patients on Children's Oncology Group (COG) Clinical Trials.

Authors

Michael J Burke
Meenakshi Devidas
Kelly Maloney
Anne Angiolillo, George Washington University
Reuven Schore
Kimberly Dunsmore
Eric Larsen
Len A Mattano
Wanda Salzer
Stuart S Winter
William Carroll
Naomi J Winick
Mignon L Loh
Elizabeth Raetz
Stephen P Hunger
Archie Bleyer

Document Type

Journal Article

Publication Date

7-1-2018

Journal

Leukemia & lymphoma

Volume

59

Issue

7

Inclusive Pages

1624-1633

DOI

10.1080/10428194.2017.1397658

Keywords

Adolescent; Age Factors; Antineoplastic Agents; Asparaginase; Biomarkers; Child; Child, Preschool; Drug Hypersensitivity; Female; Humans; Incidence; Infusions, Intravenous; Injections, Intramuscular; Leukemia; Male; Polyethylene Glycols; Public Health Surveillance; Severity of Illness Index

APA Citation

Burke, M., Devidas, M., Maloney, K., Angiolillo, A., Schore, R., Dunsmore, K., Larsen, E., Mattano, L., Salzer, W., Winter, S., Carroll, W., Winick, N., Loh, M., Raetz, E., Hunger, S., & Bleyer, A. (2018). Severe Pegaspargase Hypersensitivity Reaction Rates (grade ≥3) with Intravenous Infusion vs. Intramuscular Injection: Analysis of 54,280 Doses Administered to 16,534 Patients on Children's Oncology Group (COG) Clinical Trials.. Leukemia & lymphoma, 59 (7). http://dx.doi.org/10.1080/10428194.2017.1397658

Peer Reviewed

1